Vir Biotechnology to Present at BofA Securities 2020 Health Care Conference

Rhea-AI Summary

Vir Biotechnology (Nasdaq: VIR) has announced that its CEO, George Scangos, Ph.D., will present virtually at the BofA Securities 2020 Health Care Conference on May 14, 2020, at 12:40 pm PT / 3:40 pm ET. Investors and interested parties can access the live webcast through the Vir website, where it will also be archived for 30 days afterward. Vir Biotechnology focuses on treating serious infectious diseases using advanced immunologic technologies and has initiatives targeting various viruses, including SARS-CoV-2 and hepatitis B.

News Market Reaction – VIR

+3.08%

+3.08% Session move

In the trading session that priced this news, VIR gained 3.08%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN FRANCISCO, May 07, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today announced that George Scangos, Ph.D., Chief Executive Officer will virtually present at the BofA Securities 2020 Health Care Conference on Thursday, May 14^th at 12:40 pm PT/ 3:40 pm ET.

A live webcast of the presentation can be accessed under Events & Presentations in the Investors section of the Vir website at www.vir.bio and will be archived there following the presentation for 30 days.

About Vir Biotechnology
Vir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting hepatitis B virus, influenza A, SARS-CoV-2, human immunodeficiency virus and tuberculosis. For more information, please visit www.vir.bio.

Contact:
Vir Biotechnology, Inc.

Investors
Neera Ravindran, MD
Head of Investor Relations & Strategic Communications
nravindran@vir.bio
+1-415-506-5256

Media
Lindy Devereux
Scient PR
lindy@scientpr.com
+1-646-515-5730

FAQ

What is the date of Vir Biotechnology's presentation at the BofA Securities Health Care Conference?

Vir Biotechnology's presentation is scheduled for May 14, 2020.

Who will present at the BofA Securities 2020 Health Care Conference for Vir Biotechnology?

The presentation will be made by CEO George Scangos, Ph.D.

Where can I watch the Vir Biotechnology presentation from the BofA Securities conference?

The presentation can be accessed live on the Vir Biotechnology website.

What technologies does Vir Biotechnology focus on for treating infectious diseases?

Vir Biotechnology utilizes advanced immunologic insights and technologies to treat diseases like hepatitis B and SARS-CoV-2.

What time is the Vir Biotechnology presentation at the BofA Securities conference?

The presentation is set for 12:40 pm PT / 3:40 pm ET.